Fact-checked by Grok 2 weeks ago

Paratuberculosis

Paratuberculosis, also known as Johne's disease, is a chronic, progressive, and typically fatal infectious disease that primarily affects the of animals, including , sheep, , and other hoofed species. Caused by the bacterium (MAP), an acid-fast bacillus belonging to the Mycobacterium avium complex, the disease is characterized by granulomatous , leading to , persistent , and severe despite normal in advanced stages. The is highly contagious and spreads mainly through the fecal-oral route, with young animals under six months of age being most susceptible due to their developing immune systems and behaviors that expose them to contaminated environments. Transmission can occur via ingestion of in , contaminated feed, water, or soil, as well as through , from infected dams, or even intrauterine during ; the bacterium is remarkably resilient, surviving in the environment for months to over a year under favorable conditions. Most infected animals remain subclinical carriers for years—often two or more—shedding the without showing signs, which complicates early detection and control efforts. Clinical manifestations vary by host and strain of , with typically exhibiting profuse, watery , progressive , decreased production, and (such as "bottle jaw" under the chin), while sheep and often show subtler signs like chronic without prominent . The disease is endemic worldwide, with prevalence rates in U.S. herds estimated at 20-70% in some studies, leading to substantial economic losses through reduced productivity, premature , and increased veterinary costs—potentially exceeding hundreds of millions of dollars annually in affected regions. Although primarily a veterinary concern, MAP's potential zoonotic links to human remain under investigation but are not conclusively established. Control and prevention rely on integrated management strategies, as no fully effective or curative exists; key measures include testing and infected animals, implementing to minimize exposure (e.g., clean calving areas and of ), and herd-level surveillance using tools like serology, fecal , or for , though these methods have limitations in sensitivity during early infection. Voluntary control programs, such as those coordinated by the USDA, emphasize education and to reduce prevalence, but eradication is challenging due to the long and asymptomatic shedding.

Overview and History

Definition and Importance

Paratuberculosis, also known as Johne's disease, is a chronic infectious disease that causes granulomatous enteritis in the intestines of animals, leading to progressive debilitation and wasting. The disease primarily affects domestic ruminants such as , sheep, and , but it also occurs in species including deer and other cervids, which can serve as reservoirs for the pathogen. Caused by the bacterium (MAP), it was first described in by Heinrich Albert Johne and Langdon Frothingham in a cow exhibiting chronic and . The economic significance of paratuberculosis in production is substantial, with infected herds experiencing reduced milk yield, slower , and premature of animals, resulting in annual losses estimated at approximately $33 per cow in operations due to decreased . These impacts are compounded by trade restrictions on animals and from infected herds, which limit international and necessitate costly control programs. In agricultural settings, the disease contributes to broader inefficiencies, as MAP can persist in the environment for extended periods, complicating herd management and efforts. From a and agricultural perspective, paratuberculosis raises concerns due to MAP shedding in , , and potentially , leading to environmental and risks of through raw products or undercooked tissues. Although mitigates much of the risk in , the presence of viable MAP in retail products underscores the need for vigilant to protect supply chains and maintain consumer confidence in -derived foods. Overall, the disease's insidious and long make it a persistent challenge in , influencing global health strategies.

Historical Background

Paratuberculosis, also known as Johne's disease, was first described in 1895 by German veterinarians Heinrich Albert Johne and Langdon Frothingham, who observed a chronic diarrheal condition in from a herd in , initially mistaking it for a form of bovine due to similar granulomatous intestinal lesions. Their report detailed the progressive wasting and persistent diarrhea in affected animals, marking the initial recognition of the disease as a distinct enteric disorder in ruminants. The causative bacterium was isolated in 1912 by British bacteriologist Frederick Twort, who cultured a slow-growing, acid-fast organism from infected bovine tissues, proposing the name Mycobacterium enteritidis chronicae pseudotuberculosae bovis Johne. This breakthrough was soon corroborated by French researchers Henri Vallée and Pierre Rinjard, who confirmed the pathogen's role through experimental studies, solidifying its mycobacterial nature despite early challenges in culturing due to its fastidious growth requirements. These efforts highlighted persistent misconceptions, as the disease's lesions and acid-fast bacilli were frequently confused with those of true bovine tuberculosis caused by , leading to diagnostic errors and debates over its etiology until the 1920s. The bacterium's nomenclature evolved significantly over the decades; initially named Mycobacterium johnei in honor of Johne, it was reclassified as Mycobacterium paratuberculosis in the 1920s to reflect its close relation to but distinction from tuberculosis pathogens. By the 1990s, genomic and phenotypic analyses integrated it into the Mycobacterium avium complex as Mycobacterium avium subsp. paratuberculosis (MAP), a designation formalized in taxonomic revisions that emphasized its subspecies status. Key milestones included early vaccine development in the 1920s, when Vallée and Rinjard tested live attenuated strains administered subcutaneously to calves, achieving partial protection against experimental challenge despite variable efficacy and concerns over post-vaccination reactions. By the 2000s, paratuberculosis gained recognition as a in several countries, including and , prompting mandatory reporting and surveillance to address its economic impact on industries. Debates on its zoonotic potential emerged in the late 20th century, fueled by hypothesized links to human .

Etiology and Transmission

Causative Agent

Paratuberculosis, also known as Johne's disease, is caused by Mycobacterium avium subsp. paratuberculosis (MAP), a member of the * within the genus . This subspecies is classified as a Gram-positive, aerobic, nonmotile, non-spore-forming bacterium belonging to the phylum Actinobacteria. MAP exhibits characteristic morphological features as slender, rod-shaped acid-fast , measuring 0.5 to 1.5 μm in diameter, with a dense, waxy rich in mycolic acids that confers resistance to decolorization by acid-alcohol. It is an intracellular with an extremely slow growth rate, typically exhibiting a generation time exceeding 24 hours, which makes laboratory cultivation challenging. Growth requires supplementation with mycobactin, an iron-chelating that MAP cannot synthesize independently, distinguishing it from other mycobacteria; without it, colonies fail to form on solid media like Herrold's egg yolk agar. Genetically, MAP strains are categorized into three primary types based on polymorphisms in insertion sequences such as IS1311 and IS900: Type I (sheep-type), predominantly associated with ovine hosts and characterized by slower growth; Type II (cattle-type), more common in bovine populations and faster-growing; and Type III (intermediate), showing hybrid patterns between the two. A bison-type variant, often aligned with Type II but with distinct genomic markers, has been identified in cervid and reservoirs. These strain differences influence host specificity and are used for epidemiological typing. MAP demonstrates remarkable environmental persistence, surviving in , , and for over a year under shaded, moist conditions that limit and UV exposure; for instance, viability has been documented up to 48 weeks in shaded water sediments and 270 days in natural sources. This resilience is attributed to its thick and ability to form biofilms or enter . The MAP genome is relatively large at approximately 4.8 million base pairs, with about 1.5% consisting of repetitive elements, including 14–17 copies of the MAP-specific insertion sequence IS900, which facilitates strain differentiation through PCR-based analysis.

Modes of Transmission

Paratuberculosis, caused by (MAP), is primarily transmitted through the fecal-oral route, where susceptible animals, especially young calves, ingest the from contaminated feed, , , or shed by infected adults. This route is facilitated by the heavy shedding of MAP in feces from clinically or subclinically infected , leading to environmental contamination that young animals encounter during grazing or nursing. Studies indicate that calves are most vulnerable in the first few months of life due to their immature immune systems and behaviors that increase exposure to fecal matter. Vertical transmission occurs from dam to offspring, either or through and milk, providing a direct pathway for early . has been documented in up to 40% of cases in high-prevalence herds, where MAP crosses the placental barrier to infect the . Additionally, MAP can be present in and milk from infected dams, with feeding pooled colostrum from ELISA-positive cows increasing risk by odds ratios as high as 87.3. Although less common than fecal-oral spread, vertical transmission contributes to persistent within-herd by establishing lifelong carriers early in life. Horizontal transmission spreads between animals and herds via indirect contact with contaminated materials, including shared equipment, bedding, or pastures, as well as through animal movement. Calves exposed to adult through contaminated udders or maternity pens face significantly elevated risks, with odds ratios ranging from 4.59 to 30.5 depending on the duration and intensity of exposure. Herd-to-herd spread often results from introducing subclinically infected animals, which can silently propagate the without immediate detection. Bioaerosols in barn dust represent an emerging horizontal route, where viable MAP particles may be inhaled or ingested by nearby calves. The environmental persistence of MAP enhances its transmissibility, as the bacterium can survive in , , and for up to 55 weeks, maintaining in moist conditions and facilitating long-term of sources and grazing areas. , such as rabbits, may act as vectors by harboring MAP and excreting it into shared environments, potentially bridging transmission between populations. Several risk factors amplify transmission dynamics, including high stocking density, which promotes fecal in shared spaces, and poor practices that allow prolonged environmental survival of MAP. Group-housing of calves or periparturient cows increases contact with shedders, with count ratios up to 2.0 for in such settings, while introducing animals from unknown MAP status herds remains a critical for new outbreaks. Calves spending extended time in contaminated yards, exceeding 429 minutes, exhibit a 3.68-fold higher , underscoring the role of in mitigating spread.

Clinical Presentation

Signs and Symptoms

Paratuberculosis, also known as Johne's disease, typically has a long of 2 to 5 years in , during which infected animals often remain subclinical for life without developing overt signs but begin shedding the causative bacterium, Mycobacterium avium subsp. paratuberculosis (), in their feces, facilitating environmental transmission. This subclinical phase is characterized by the absence of visible clinical manifestations, though infected animals may show subtle reductions in productivity, such as slightly lower weight gains or milk yields, while appearing otherwise healthy. The prolonged incubation allows widespread dissemination within herds before detection becomes feasible. As the disease progresses to the clinical phase, affected ruminants exhibit progressive and despite maintaining a normal appetite, a hallmark sign that distinguishes paratuberculosis from other wasting conditions. In , chronic often develops, typically described as profuse and pipestream-like; this leads to and further debilitation. Additional signs in include a marked decrease in milk production and intermandibular known as "bottle jaw," contributing to economic losses in affected herds. becomes pronounced, with animals appearing unthrifty and weak, though fever is absent. Species-specific variations influence the presentation and progression of clinical signs. In , the disease advances slowly, with clinical manifestations rarely appearing before 2 years of age and often not until later adulthood. Conversely, paratuberculosis progresses more rapidly in sheep and goats, where is the dominant feature, accompanied by and trailing behind the flock; is less consistent than in . In these small ruminants, additional signs may include rough coat or wool loss in sheep and occasional in goats, exacerbating mobility issues. In advanced stages across species, intensifies from ongoing fluid loss, leading to profound weakness, recumbency, and increased susceptibility to secondary infections due to . Ultimately, affected animals succumb to and or are euthanized for welfare reasons, as the disease is invariably fatal once clinical signs emerge.

Pathophysiology

Paratuberculosis, caused by (MAP), begins with the bacterium's entry through the intestinal mucosa, primarily targeting the ileal Peyer's patches in young ruminants. MAP is translocated across the epithelial barrier via M cells overlying the lymphoid follicles, followed by rapid by subepithelial and intraepithelial macrophages within hours of . This uptake is facilitated by the bacterium's adherence to the mucosal surface, often occurring through fecal-oral routes such as contaminated feed or . Once phagocytosed, MAP exhibits remarkable intracellular survival strategies that enable its persistence within macrophages. The pathogen resides in early phagosomes, evading fusion with lysosomes by inhibiting phagosomal maturation and acidification, allowing intracellular replication over 4–8 days. MAP further modulates the host by promoting a Th1/Th2 imbalance, suppressing pro-inflammatory Th1 cytokines like IFN-γ while favoring Th2 cytokines such as IL-4, IL-10, and IL-5, which impair effective and bacterial clearance. This immune modulation contributes to the bacterium's ability to disseminate from the initial site via infected macrophages in the bloodstream and lymphatics. The chronic infection triggers granulomatous inflammation in the intestinal mucosa and submucosa, particularly in the distal and . Multinucleated giant cells and epithelioid macrophages aggregate around MAP-laden cells, forming granulomas that disrupt normal tissue architecture, leading to epithelial corrugation, villous atrophy, and progressive thickening of the gut wall. These lesions impair nutrient absorption, culminating in syndromes as the disease advances. Concurrently, MAP induces systemic immune suppression, characterized by a reduction in CD4+ T-cell numbers and an increase in regulatory T-cells, which further promotes bacterial persistence and hinders the development of protective . Systemic effects extend beyond the gut, with MAP spreading to mesenteric nodes and other lymphoid tissues, exacerbating and contributing to . This results in due to chronic protein leakage into the gut lumen, often manifesting as in advanced stages. The overall underscores MAP's stealthy exploitation of host defenses, leading to a protracted, non-resolving that persists for years.

Diagnosis

Diagnostic Methods

Diagnosis of paratuberculosis, caused by Mycobacterium avium subsp. paratuberculosis (), relies on a combination of direct detection and indirect immunological methods to identify infection in ruminants, particularly in subclinical stages where clinical signs may be absent. These approaches target the slow-growing bacterium in fecal, tissue, or samples, with selection depending on the testing goals such as or . Bacteriological remains the gold standard for definitive due to its specificity in isolating viable MAP organisms. Bacteriological culture involves inoculating fecal or tissue samples onto specialized media to grow MAP, which requires mycobactin supplementation for growth. The traditional medium, Herrold's egg yolk agar (HEYA), enriched with mycobactin J, supports the isolation of MAP from contaminated samples like , though steps are necessary to eliminate competing . typically lasts 8 to 16 weeks at 37°C due to MAP's slow growth rate, with colonies appearing as small, grayish, opaque formations confirmed by acid-fast staining. Serological tests detect host antibodies against , providing a non-invasive screening tool for infected herds. Enzyme-linked immunosorbent assay () is the most widely used, employing MAP-specific protoplasmic antigens or whole-cell lysates to quantify (IgG) in , , or samples. Commercial kits, such as those from IDEXX or VMRD, offer high-throughput testing suitable for large-scale , identifying subclinical infections in animals with moderate antibody levels. PCR-based molecular tests amplify MAP-specific genetic elements for rapid detection without cultivation. Targeting the IS900 insertion sequence, a multicopy element unique to MAP, real-time quantitative PCR (qPCR) on fecal or tissue DNA offers results within hours, enabling early identification of shedders in herds. These assays, often performed on pooled samples for cost-efficiency, confirm MAP presence through fluorescence-based detection of amplified products, though they require prior DNA extraction to handle inhibitors in clinical specimens. Histopathology examines tissue biopsies, typically from the or mesenteric nodes, to observe characteristic lesions of paratuberculosis. Sections stained with hematoxylin and reveal granulomatous with infiltration and multinucleated giant cells, while Ziehl-Neelsen acid-fast staining highlights MAP as red, rod-shaped organisms within granulomas. This method confirms chronic infection in postmortem or surgical samples but is less sensitive for low-burden cases. Emerging methods like (LAMP) provide field-applicable alternatives to by amplifying IS900 under constant temperature without thermal cycling equipment. LAMP assays detect MAP DNA in feces or within 60 minutes using visual or dye-based endpoints, offering simplicity for on-site testing in resource-limited settings. Validation studies demonstrate LAMP's comparable to qPCR for direct sample , facilitating quicker herd management decisions. More recent advances as of 2025 include phage-based assays that use bacteriophages to amplify and detect viable , often combined with qPCR for results in one day, improving sensitivity for live in or . MicroRNA (miRNA) profiling of blood or serum, integrated with and predictive modeling, shows promise for early subclinical detection with preliminary sensitivities around 70-80% in studies. Additionally, (NIRS) coupled with aquaphotomics analyzes water spectral patterns in or samples non-invasively, achieving high accuracy (up to 95% in validation) for diagnosing without traditional lab processing. These methods are under further validation but offer potential for faster, cost-effective screening in herds.

Challenges in Detection

Detecting paratuberculosis, caused by Mycobacterium avium subsp. paratuberculosis (MAP), presents significant challenges due to the pathogen's biology and the limitations of available diagnostic methods, particularly in early infection stages where bacterial loads are minimal and shedding is inconsistent. These issues often result in false negatives, delaying intervention and complicating herd management. In early and subclinical stages, diagnostic tests exhibit low sensitivity primarily because of intermittent fecal shedding and low bacterial loads, which can drop to undetectable levels even in infected animals. For instance, fecal culture, considered the gold standard, achieves only 23–29% sensitivity in subclinical cases compared to approximately 70% in clinical stages, as infected animals may shed MAP sporadically or at concentrations below detection thresholds. Similarly, enzyme-linked immunosorbent assay (ELISA) sensitivity ranges from 7–22% in early non-shedding phases to 15% in subclinical infections, missing the majority of cases before antibody responses develop. Polymerase chain reaction (PCR) assays face additional hurdles from fecal inhibitors and low DNA yields, further reducing reliability in these stages. Specificity concerns arise from cross-reactivity with other mycobacteria, leading to false positives in serological and molecular tests. can react with environmental mycobacteria or M. bovis, compromising its accuracy in regions with co-endemic infections. methods, while targeting MAP-specific elements like IS900, may amplify homologous sequences from non-pathogenic Mycobacterium avium complex members, necessitating optimized primers to minimize errors. Fecal also risks false positives from environmental contamination or bacterial pass-through without active infection. Practical barriers exacerbate detection difficulties, including the time-intensive nature of bacterial , which requires 8–12 weeks due to MAP's slow growth, and high costs associated with repeated testing. Definitive confirmation often demands necropsy with histopathological examination and , which is invasive and feasible only post-mortem, limiting antemortem screening. At the level, testing strategies struggle to certify MAP-free status because individual test are insufficient to rule out silent infections, particularly in low- settings. Pooled fecal or environmental sampling offers of 26–100% but cannot guarantee absence, as false negatives persist from intermittent shedders; voluntary programs thus emphasize reduction rather than absolute freedom. ELISA-based screening performs better for estimation ( 40–100%) but low individual (30–50%) allows undetected carriers to perpetuate transmission. Gaps in and environmental testing further hinder comprehensive , as standardized protocols are lacking for detecting in non-domestic reservoirs or open pastures where contamination dilutes samples. Environmental culture sensitivity varies widely (24–95%), undermined by inconsistent sampling sites and exposure to inhibitors, while diagnosis faces additional constraints from taxonomic diversity and capture challenges, impeding validation of tests across species.

Epidemiology

Global Prevalence

Paratuberculosis, caused by Mycobacterium avium subsp. paratuberculosis (), is endemic worldwide in ruminants, with a survey of 48 countries indicating that the disease is present in populations across all continents, and in 58% of 31 countries providing estimates, more than 20% of , sheep, or herds are infected. Herd-level varies widely but is generally high, often exceeding 50% in affected regions, while animal-level within infected herds typically ranges from 5% to 15%. Underreporting is common, with 74% of notifiable countries lacking comprehensive surveillance data, leading to underestimation of true global occurrence. Prevalence is notably higher in dairy cattle herds, estimated at 20-70% in the United States (as of 2007) and parts of Europe (apparent seroprevalence 38-68% as of 2009), compared to 5-20% in beef cattle operations, due to differences in management intensity and animal density. In the United States, approximately 68% of dairy herds are infected at the herd level (as of 2007). Regional variations are pronounced; the disease is endemic in sheep populations in Australia and New Zealand, with herd-level prevalence estimated at 2-10% in Australia and up to 76% in New Zealand, while it is emerging in Asia and Africa amid livestock intensification and expanding dairy systems. Species-specific patterns show the highest occurrence in cattle, primarily associated with MAP Type II strains, whereas sheep and goats are more affected by Type I strains, and wildlife such as deer exhibit notable infections in endemic areas. Trends indicate increasing prevalence driven by global animal trade and movement of subclinically infected , which facilitates across borders, though targeted interventions have led to declines in some regions. In the , voluntary test-and-cull programs under the National Johne’s Management Plan have reduced within-herd prevalence and lowered average test values in participating herds from 2013 to 2022. Key risk factors include importation of infected animals and intensive farming practices that promote fecal-oral transmission in shared environments, as highlighted in (WOAH) reports.

Morbidity and Mortality

Paratuberculosis, also known as Johne's disease, imposes a significant on populations, with morbidity rates varying by infection stage and host species. In infected herds, clinical cases typically affect 5-10% of adult animals, manifesting as progressive and , while subclinical infections are far more prevalent, impacting 20-50% or more of the herd and contributing to insidious productivity declines without overt signs. These subclinical cases often go undetected for years, allowing widespread within herds and amplifying the overall morbidity burden. Mortality from paratuberculosis is generally low in direct terms but substantial indirectly through of infected animals to prevent spread. In , annual direct mortality rates are approximately 1%, though cull rates can elevate total losses to 1-5% per year due to early removal of subclinically affected individuals. In high-prevalence herds, lifetime mortality and can reach up to 20%, particularly as infections progress to clinical stages leading to and death. The disease exerts profound production impacts, reducing animal performance and generating economic losses across affected industries. Subclinically infected experience a 5-16% drop in milk yield, alongside a 16-20% increase in days open, equating to roughly 15% reduced fertility rates, which collectively result in annual losses of approximately $20-80 per infected cow. These effects stem from chronic intestinal impairing nutrient absorption, leading to diminished energy for and . Species differences influence the severity of morbidity and mortality, with showing heightened vulnerability compared to . In , particularly young animals, mortality can reach up to 33% in severe outbreaks, driven by rapid disease progression and higher susceptibility to clinical manifestations like severe wasting. Adult , in contrast, exhibit lower mortality rates, often below 5% annually, though subclinical effects on productivity remain comparable across . Long-term consequences include herd depopulation through sustained and genetic losses from the removal of high-producing animals, which disrupts programs and herd over generations. In unmanaged herds, these factors can lead to persistent productivity erosion, with overall economic burdens estimated at $200-250 million annually in the U.S. dairy industry (as of early 2000s).

Control and Management

Prevention Strategies

Prevention of paratuberculosis, also known as Johne's disease, primarily relies on measures to limit the introduction of Mycobacterium avium subsp. paratuberculosis () into herds and reduce within-herd transmission through targeted management practices. These strategies focus on breaking fecal-oral transmission routes, which occur via contaminated , , and environmental sources, by isolating susceptible young animals and minimizing exposure to infected adults. Biosecurity protocols are foundational, including quarantine of new animals with testing before integration, typically for several weeks to allow for diagnostic results, to prevent importing infected stock. Test-and-cull programs involve regular serological or fecal testing of adult animals, followed by removal of positive cases to lower herd prevalence; for instance, annual testing of at least 30 cows in dairy herds has been shown to support herd classification under voluntary programs. Separate calving areas, cleaned and disinfected between uses, isolate newborns from manure-contaminated environments, reducing early-life infection risk in controlled studies. Hygiene practices emphasize manure management to curb environmental persistence of MAP, which can survive for over a year in soil and bedding; recommendations include applying manure only to cropland rather than pastures grazed by young stock and using separate equipment for feed handling to avoid cross-contamination. Facilities should undergo routine disinfection with effective agents like phenolic compounds or accelerated hydrogen peroxide disinfectants, and overstocking must be avoided to limit animal density and fecal buildup in housing areas. Clean water troughs and feed bunks regularly further mitigate oral exposure. Management approaches include early of calves at 2-4 hours post-birth to minimize ingestion of MAP-laden or milk from infected , often supplemented by feeding pasteurized milk or milk replacers from test-negative sources. rotation strategies rest pastures for at least one year after use by adults, preventing young animals from foraging on contaminated areas and reducing rates in herds. Raising replacements in isolated areas, separate from adults for the first year, further limits exposure. Certification programs, such as the USDA Voluntary Bovine Johne's Disease Program, enable herds to achieve MAP-free status through progressive levels (1-6) requiring risk assessments, implementation, and repeated testing—typically or fecal culture every 10-14 months—to verify low risk and provide certified low-prevalence breeding stock. Similar state-level programs, like Utah's, classify herds based on testing outcomes and management adherence. Environmental controls involve testing feed and water sources for MAP contamination, particularly in areas with high wildlife prevalence, and installing barriers such as to restrict access by deer or other reservoirs that can shed the . These measures, integrated into plans, have demonstrated reduced new infections in monitored programs across multiple countries.

Treatment and Vaccination

There is no curative treatment for paratuberculosis in infected , as the causative agent, Mycobacterium avium subsp. paratuberculosis (MAP), persists intracellularly within macrophages, rendering antibiotics largely ineffective at eliminating the infection. Experimental antibiotic regimens, such as combinations of rifampin and , may temporarily alleviate clinical signs like and in some cases but require lifelong administration and often lead to upon cessation. These treatments are not approved for use in food-producing due to residue concerns in and , limiting their practical application in veterinary . Supportive care focuses on symptom management to improve and productivity in affected animals. Nutritional supplements, such as , can help address deficiencies associated with and support immune function, potentially slowing disease progression. Anti-diarrheal agents and fluid therapy may also be used to control and imbalances during acute episodes, though these measures do not address the underlying infection. Vaccination represents the primary intervention for post-infection management, with inactivated whole-cell vaccines, such as those based on killed MAP bacterins adjuvanted with mineral oil, widely used in cattle to reduce clinical disease severity and bacterial shedding. These vaccines, administered via subcutaneous injection to young animals, can decrease fecal shedding by 50-90% in field trials, with variable effects on clinical incidence, though they do not prevent initial infection or MAP colonization. Cattle-specific formulations differ from multi-species vaccines like Gudair, which is approved for sheep and goats and similarly reduces mortality and transmission when given subcutaneously to neonates. Experimental DNA vaccines targeting MAP antigens have shown promise in animal models by eliciting Th1 immune responses and limiting tissue burden, but they remain under development and are not commercially available. Key limitations of current vaccines include interference with diagnostic tests for bovine tuberculosis due to , necessitating regulatory restrictions in some regions, and variable efficacy influenced by MAP strain, animal age at , and herd management practices. Despite these challenges, consistent in endemic herds can lower overall and economic losses over time.

Zoonotic Concerns

Human Health Risks

Paratuberculosis, caused by (MAP), poses potential zoonotic risks to humans through various exposure routes, primarily fecal-oral involving contaminated food and environmental sources. The main pathways include consumption of unpasteurized and products from infected ruminants, ingestion of undercooked such as from contaminated animals, and direct environmental contact with feces, , or in agricultural settings. Farmers and veterinarians face elevated exposure risks due to occupational handling of infected and manure, which can lead to aerosolized or dust-borne dissemination of the . Waterborne is also possible via contaminated surface or in farming areas. Detection of MAP in humans has been reported through molecular and culture methods in various bodily fluids and tissues, indicating possible subclinical infections. MAP DNA and viable isolates have been identified in , , and , with studies isolating the bacterium from of affected individuals and culturing it from peripheral samples at rates up to 50% in certain cohorts. Seroprevalence of anti-MAP antibodies varies widely across populations, ranging from 10% to 50% in some regions, such as 23.4% in northern and 34% in specific urban-rural areas, suggesting widespread but often exposure. These findings highlight the pathogen's ability to persist in human hosts, though the remains under investigation. Occupational exposure among workers and farmers is a notable concern, with evidence of higher levels compared to the general —up to 25% seropositivity in high-risk groups versus around 5% in controls—due to prolonged contact with infected herds. Foodborne remains debated, particularly regarding MAP survival in pasteurized , where viable organisms have been cultured from retail samples in multiple countries, though efficacy is contested. Similarly, MAP has been detected in retail and products, raising concerns about undercooked consumption as a vector, especially in regions with high animal prevalence. Preliminary research suggests non-Crohn's associations with MAP exposure, including possible links to and , based on elevated odds ratios of 2.91–9.95 for and 6.5–7.99 for in serological and molecular studies. These connections are supported by higher detection rates in affected patients, potentially involving immune dysregulation triggered by chronic infection, though causation is not established and requires further validation. The hypothesis that Mycobacterium avium subsp. paratuberculosis (MAP) plays a causative or contributing role in posits that the bacterium establishes a persistent in the human intestine, leading to chronic inflammation through mechanisms such as immune evasion and molecular mimicry, where MAP antigens resemble host proteins and trigger autoimmune responses. This parallels the bacterium's pathogenesis in Johne's disease in ruminants, where MAP induces a similar granulomatous . Supporting evidence includes detection of higher levels of MAP in tissues and blood from Crohn's patients compared to controls, using techniques like polymerase chain reaction (PCR) and culture. Early studies by Naser and colleagues in the early 2000s demonstrated MAP DNA via in 46% of Crohn's patients' buffy coat samples versus 13% in healthy controls, and viable MAP was cultured from the blood of up to 50% of Crohn's cases but rarely from non-Crohn's samples. Animal models infected with MAP, particularly in ruminants, reproduce chronic with granulomatous akin to Crohn's , while limited non-ruminant models show MAP inducing intestinal barrier disruption and . A seminal 2007 meta-analysis of PCR-based studies reported a pooled of 7.01 (95% CI 3.95-12.4) for MAP detection in Crohn's intestinal tissues compared to non-inflammatory bowel disease controls, indicating a specific . Key clinical studies have explored anti-MAP antibiotic therapies, such as combinations of and rifabutin, which have induced remission in subsets of Crohn's patients. In a 2020 , 70% of treated patients achieved clinical remission lasting 3-23 years (median 8.5 years), with sustained benefits in those confirmed MAP-positive. Another 2020 using targeted anti-MAP regimens (rifabutin, , , plus adjuncts) reported endoscopic remission in 66% of active Crohn's cases to . These findings suggest potential efficacy in MAP-associated subsets, though larger randomized trials like the 2007 Selby study showed no overall benefit across all patients.00801-3/fulltext) Counterarguments highlight inconsistent MAP isolation across studies, with many failing to detect the bacterium in Crohn's tissues using standard methods, attributed to its low abundance or cell-wall-deficient forms. has not fulfilled in humans, as it is not consistently isolated from all cases, transmission experiments are unethical, and re-isolation post-infection is challenging due to the bacterium's dormancy. Alternative etiologies, such as genetic factors including mutations (present in 20-30% of Crohn's patients and conferring 2-4 fold increased risk), emphasize dysregulated innate immunity over infectious triggers. The link between MAP and Crohn's remains a debated zoonotic association, with authoritative bodies viewing it as possible but unproven; the Crohn's & Colitis Foundation's 2018 position statement concludes that while MAP may trigger disease in genetically susceptible individuals, conclusive evidence of causality is lacking. Ongoing debate underscores the need for improved diagnostics and targeted trials to clarify MAP's role.

Regulations and Research

Veterinary and Public Health Regulations

In the , paratuberculosis is categorized as a Category E disease under Regulation (EU) 2016/429 (Animal Health Law), which emphasizes surveillance and voluntary control measures at the level rather than mandatory notification, allowing flexibility for national programs to mitigate spread in populations. Earlier directives, such as Council Directive 64/432/EEC on animal health conditions for intra-Community trade in bovine animals, indirectly influenced control by requiring health certifications that could include paratuberculosis testing in high- areas. In contrast, the implements a voluntary approach through the USDA's Uniform Program Standards for the Voluntary Bovine Johne's Disease Control Program, established in 2002 to reduce via herd risk assessments, testing, and management without federal mandates. International trade regulations for paratuberculosis align with (WOAH) standards outlined in the Terrestrial Animal Health Code, Chapter 8.14, which recommends that importing countries require certification of freedom from the or pre-export testing for live ruminants and to prevent introduction into naive herds. For MAP-positive herds, WOAH guidelines endorse and movement restrictions, with many nations, such as those in the and exporting to regions like , mandating serological or fecal testing prior to export to ensure compliance and minimize global dissemination. The WOAH Terrestrial Code, Chapter 8.14, classifies paratuberculosis as a multi-species affecting ruminants and other mammals, urging member countries to implement ongoing to monitor incidence and inform trade decisions. Public health regulations focus on mitigating potential zoonotic transmission through food safety measures, with the U.S. Food and Drug Administration (FDA) and USDA enforcing pasteurization standards under the Pasteurized Milk Ordinance (PMO), which require heating milk to at least 72°C for 15 seconds—conditions proven to inactivate Mycobacterium avium subsp. paratuberculosis (MAP) and protect the commercial milk supply. Monitoring programs in the milk supply chain, including periodic testing for MAP viability, are integrated into FDA oversight to verify compliance, particularly in regions with high dairy herd prevalence. Enforcement mechanisms vary by but include penalties for non-reporting in areas where paratuberculosis is designated reportable, such as state-level requirements in the U.S. (e.g., mandates immediate notification to the state veterinarian, with fines up to $500 per violation) and EU member states under national implementations of Regulation (EU) 2016/429, where failure to report surveillance data can result in administrative sanctions or loss of subsidies. To encourage participation in control efforts, governments provide subsidies for testing and management in high-risk areas, such as USDA cost-sharing for herd assessments in the U.S. Voluntary Program (covering up to 100% of initial risk evaluations) and EU-funded national schemes that reimburse up to 50% of diagnostic costs in endemic zones. These incentives aim to balance economic burdens while addressing zoonotic concerns through enhanced veterinary oversight.

Current Research Directions

Recent advancements in paratuberculosis research emphasize innovative diagnostics, vaccine strategies, zoonotic investigations, host genetic factors, and environmental dynamics to address persistent challenges in disease control. Whole-genome sequencing (WGS) has emerged as a key tool for tracking (MAP) strains, enabling precise phylogenetic analysis and identification of transmission pathways in populations. For instance, a 2025 study provided the first complete WGS of a novel MAP isolate, revealing genetic variations that support strain-specific surveillance in endemic regions. Similarly, comprehensive genomic analyses in 2025 identified and virulence genes in MAP isolates, facilitating targeted outbreak investigations. Complementing these, (AI) and are being integrated into histopathological diagnostics, with explainable AI models achieving high accuracy in detecting MAP-induced lesions in tissue samples from infected ruminants. A 2023 approach also identified signatures associated with MAP infection in , enhancing non-invasive diagnostic potential through fecal analysis. Vaccine development focuses on subunit and attenuated candidates to overcome limitations of existing whole-cell vaccines, such as interference with tuberculosis diagnostics. A 2023 study demonstrated that a recombinant based on MAP antigens protected mice against virulent challenge, reducing bacterial loads in tissues by up to 90% and alleviating . In goats, experimental inactivated vaccines administered via alternative routes showed promising efficacy in 2024 trials, with subcutaneous delivery reducing fecal shedding by approximately 60-80% compared to controls. initiatives, including a Danish project on novel s, aim to develop formulations that elicit strong without diagnostic , with preclinical data indicating reduced clinical signs in calves. For zoonotic aspects, a phase 1b in 2025 evaluated viral-vectored MAP vaccines (ChAdOx2 and MVA) in humans with (IBD), confirming safety and without adverse events. Ongoing research explores attenuated live vaccines, with a 2025 evaluation of eight candidates in mice reporting up to 70% reduction in MAP shedding post-challenge. Zoonosis investigations increasingly incorporate longitudinal cohort studies and meta-analyses to clarify MAP's role in human IBD, particularly Crohn's disease. A 2024 study analyzed human antibodies against MAP in serum samples from IBD patients, finding higher seroprevalence in Crohn's cases compared to controls, suggesting persistent exposure. Meta-analyses in 2024 confirmed elevated cytokine profiles (e.g., IFN-γ and IL-10) in MAP-positive individuals with Crohn's, linking bacterial persistence to dysregulated immune responses. Microbiome interactions are a focus, with a 2024 analysis revealing that MAP infection alters gut microbiota composition in multiple sclerosis patients—a condition overlapping with IBD pathways—potentially exacerbating inflammation through reduced microbial diversity. These findings support expanded cohort monitoring to assess dietary and therapeutic interventions targeting MAP-microbiome dynamics. Host genetics research prioritizes identifying resistance loci to inform programs in . The SLC11A1 , involved in function, has been associated with MAP susceptibility; a 2024 study identified specific single nucleotide polymorphisms (SNPs) in SLC11A1 that correlate with lower infection rates in , explaining up to 15% of variance. Integrated genomic evaluations in 2024 advanced single-step methods to predict , incorporating SLC11A1 and other loci like TLR2 for genomic selection in herds. Preprints from 2025 further validated (GT)n variations in SLC11A1's 3'UTR as markers for in ruminants, guiding cost-effective strategies to reduce herd prevalence over generations. Environmental modeling efforts examine MAP survival under changing conditions and advocate one-health frameworks integrating reservoirs. A 2024 modeling study quantified MAP decay rates in and , predicting prolonged environmental persistence (up to 6-12 months) under warmer, moist scenarios influenced by variability, which could expand risks. One-health approaches emphasize integration, with a 2024 systematic review in the highlighting MAP circulation in wild ruminants as a bridge to domestic herds, recommending networks to mitigate spillover. A 2022 analysis framed paratuberculosis as a one-health , urging interdisciplinary models that link habitats, shifts, and agricultural practices to prevent zoonotic amplification.

References

  1. [1]
    Introduction - Diagnosis and Control of Johne's Disease - NCBI - NIH
    Johne's disease (JD), sometimes called paratuberculosis, is a chronic, progressive intestinal disease caused by infection with Mycobacterium avium subsp.
  2. [2]
    [PDF] Paratuberculosis-Johne's Disease
    Oct 20, 2017 · Paratuberculosis is a chronic intestinal disease, caused by Mycobacterium avium ssp. paratuberculosis, that primarily affects ruminants and ...
  3. [3]
    Johne's Disease in Livestock
    Johne's disease (pronounced "yo-knees") is an infection of the small intestine that affects cattle, sheep, goats, and other ruminants (hoofed animals).<|control11|><|separator|>
  4. [4]
    The economic impact and control of paratuberculosis in cattle
    Paratuberculosis (also called Johne's disease) is a chronic disease caused by Mycobacterium avium ssp. paratuberculosis (MAP) that affects ruminants and.
  5. [5]
    Johne's disease - International Association for Paratuberculosis
    It was in 1895 that Johne and Frothingham described the disease and demonstrated the presence of acid-fast bacilli in sections of diseased intestine. The ...
  6. [6]
    Economic losses due to Johne's disease (paratuberculosis) in dairy ...
    It was estimated that approximately 1% of gross milk revenue, equivalent to US$33 per cow, is lost annually in MAP-infected dairy herds.
  7. [7]
    Economic Implications of Johne's Disease - NCBI - NIH
    International trade of animals has contributed to the global dissemination of JD. Infected animals of European origin are cited as the original source of JD in ...
  8. [8]
    Effectiveness and Economic Viability of Johne's Disease ... - Frontiers
    Jan 14, 2021 · Johne's disease (JD), or paratuberculosis, is an infectious chronic inflammatory disorder of the intestines that can affect domestic and wild ...
  9. [9]
    Mycobacterium avium ssp. paratuberculosis in the Food Supply - NIH
    Jul 15, 2021 · The bacterium is excreted into the milk within the udder, but MAP may also enter raw milk through fecal contamination during milking (3, 5).Missing: impact meat
  10. [10]
    Assessment of Food as a Source of Exposure to Mycobacterium ...
    Milk, particularly raw milk, may be a likely food source for human exposure to MAP. Given the prevalence of MAP in US cattle herds, ground beef may be a ...
  11. [11]
    Control of paratuberculosis: who, why and how. A review of 48 ...
    Jun 13, 2019 · Paratuberculosis, a chronic disease affecting ruminant livestock, is caused by Mycobacterium avium subsp. paratuberculosis (MAP).
  12. [12]
    [PDF] 1 History of Paratuberculosis - CABI Digital Library
    Drs Johne and Frothingham concluded that the disease observed in the cow was caused by the bacterium that causes. TB in birds (later called Mycobacterium avium).
  13. [13]
    [PDF] The History of Paratuberculosis - CABI Digital Library
    Twort proposed the name Mycobacterium enteriditis chronicae pseudotuberculosis bovis johne. Although Twort received full recognition for this achievement ...
  14. [14]
    Current strategies for eradication of paratuberculosis and issues in ...
    Jul 15, 2012 · Its obvious similarities with tuberculosis gave it the name of paratuberculosis, although it was clearly recognized it was not the same entity ...
  15. [15]
    Genomic epidemiology of Mycobacterium avium subsp ... - NIH
    Feb 2, 2023 · Mycobacterium avium subsp. paratuberculosis (MAP) is the pathogen responsible for paratuberculosis or Johne's Disease (JD) in ruminants ...
  16. [16]
    Development of vaccines to Mycobacterium avium subsp ... - NIH
    The first MAP vaccine, which was developed in 1926 by Vallee and Rinjard, consisted of a live non-virulent MAP and oil based adjuvants. Since then, a number of ...
  17. [17]
    Control of paratuberculosis: who, why and how. A review of 48 ...
    Jun 13, 2019 · Paratuberculosis was believed to be under-reported in 26 (74%) of the 35 countries in which it was notifiable, regardless of the geographic zone ...
  18. [18]
    The zoonotic potential of Mycobacterium avium ssp. paratuberculosis
    The zoonotic potential of Mycobacterium avium ssp. paratuberculosis has been debated for a century since it was first suggested that Crohn's disease (CD) is ...
  19. [19]
    Mycobacterium avium subsp. paratuberculosis - NCBI - NIH
    "Numerical taxonomy of mycobactin-dependent mycobacteria, emended description of Mycobacterium avium, and description of Mycobacterium avium subsp. avium subsp.
  20. [20]
    Mycobacterium avium subsp. paratuberculosis Virulence: A Review
    Dec 19, 2021 · Taxonomic Classification of MAP. Mycobacterium avium subsp. paratuberculosis is a Gram-positive bacillus, aerobic, nonmotile, non-spore ...
  21. [21]
    Estimation of Mycobacterium avium subsp. paratuberculosis Growth ...
    M. avium subsp. paratuberculosis is a slow-growing (>24-h generation time), acid-fast microorganism that has a strong tendency to form clumps (5). These ...
  22. [22]
    Mycobacterium avium Subspecies paratuberculosis: A Review - PMC
    Apr 15, 2023 · MAP is a Gram-positive, acid-fast, rod-shaped intracellular bacteria with a diameter of 0.5 to 1.5 m. The bacterial cell wall is dense and waxy ...
  23. [23]
    Culture of Mycobacterium avium subsp. paratuberculosis
    Dec 13, 2022 · It is also extremely slow growing, with a generation time of over 20 h, making it the slowest growing of the cultivatible mycobacteria (Rowe and ...
  24. [24]
    Genotype profiles of Mycobacterium avium subspecies ...
    There are three main MAP genotypes: 'sheep-type' (S) or type I, 'cattle-type' (C) or type II, and 'intermediate' or type III based on IS900 restriction fragment ...
  25. [25]
    Comparative Genomics of Mycobacterium avium Subspecies ... - NIH
    Feb 15, 2021 · Several strains of MAP have been identified, the two major groups being sheep strain MAP, which includes the Type I and Type III sub-lineages, ...
  26. [26]
    MAP, Johne's disease and the microbiome; current knowledge and ...
    May 7, 2021 · The economic impact of paratuberculosis in a cattle herd will depend on the number of animals affected, infected and infectious [16]. Animal ...
  27. [27]
    [PDF] How Mycobacterium avium paratuberculosis is affected by the ...
    Jun 8, 2011 · MAP is a very hardy organism that has been known to survive in soil or water for as long a year when fully shaded, (Whittington et al. 2004 ...
  28. [28]
    Survival of Mycobacterium avium subsp. paratuberculosis in dam ...
    Survival in water and/or sediment in the shade was for up to 48 weeks compared to 36 weeks in the semiexposed location. Survival in sediment was 12 to 26 weeks ...
  29. [29]
    The complete genome sequence of Mycobacterium avium ... - PNAS
    Approximately 1.5% (or 72.2 kb) of the Map genome is comprised of repetitive DNA like insertion sequences, multigene families, and duplicated housekeeping genes ...
  30. [30]
    Full article: Within-farm transmission of bovine paratuberculosis
    The most likely important route of MAP transmission is the fecal-oral route between infectious cows and susceptible young calves via ingestion of contaminated ...
  31. [31]
    Unravelling transmission of Mycobacterium avium subspecies ...
    Cow to calf transmission can occur in-utero, via milk/colostrum or faecal-orally. Understanding of the different transmission routes to calves is important in ...
  32. [32]
    Risk Factors Associated with Transmission of Mycobacterium avium ...
    Dec 23, 2011 · Based on the present systematic review, contact with adult cow feces appears to be the most important risk factor for MAP transmission. Contact ...<|control11|><|separator|>
  33. [33]
    NVAP Reference Guide: Johne's Disease (Control and Eradication)
    Johne's disease is a contagious, chronic, and usually fatal infection that affects primarily the small intestine of ruminants.
  34. [34]
    Johne's Module Overview
    Johne's disease is a chronic, incurable bacterial infection that primarily affects the lower small intestine of ruminants.
  35. [35]
    Johne's Disease Control Program
    Johne's, also called Paratuberculosis, is a slow progressive wasting disease with an incubation period of usually 2 or more years. Johne's is a reportable, NOT ...
  36. [36]
    Johne's Disease in Cattle - Article 1
    Some infected animals initially just appear unthrifty. Affected cattle do not generally have a fever. The signs of this disease can easily be confused with ...
  37. [37]
    Johne's disease in sheep and goats
    Jan 3, 2019 · The most consistent clinical sign in sheep and goats is chronic weight loss despite a good appetite. Although profuse diarrhea is common in ...
  38. [38]
    Paratuberculosis: The Hidden Killer of Small Ruminants - PMC
    Paratuberculosis (PTB) or Johne's disease (JD) is a chronic contagious disease of animals caused by Mycobacterium avium subsp. paratuberculosis (MAP). The ...
  39. [39]
  40. [40]
  41. [41]
  42. [42]
    3. Diagnostics | Diagnosis and Control of Johne's Disease
    A variety of tests can detect humoral antibodies to Map in bovine serum, but because only the agar gel immunodiffusion (AGID) test, the complement fixation test ...Automated Culture · Immunologic Tests · Likelihood Ratios And Roc...
  43. [43]
    Comparison of Four Different Culture Media for Isolation and Growth ...
    Several media are used for the primary isolation of M. avium subsp. paratuberculosis: (i) egg-based media like the Herrold's egg yolk medium (21) and ...Missing: MAP | Show results with:MAP
  44. [44]
    IDEXX Paratuberculosis Verification Ab Test
    The IDEXX Paratuberculosis Verification ELISAs are for the detection of MAP-specific antibodies in bovine milk, serum or plasma, and more.
  45. [45]
    Mycobacterium avium subspecies paratuberculosis Antibody Test ...
    This enzyme-linked immunosorbent assay (ELISA) detects antibodies in caprine serum, bovine serum and bovine milk to Mycobacterium avium subsp. paratuberculosis ...
  46. [46]
    ELISA Serodiagnosis of Johne's Disease in Cattle - PubMed
    An ELISA test for the serodiagnosis of M. paratuberculosis in cattle has been developed. The test is based on antigen 60 from BCG.
  47. [47]
    Rapid and Sensitive Detection of Mycobacterium avium subsp ...
    DNA purified by this sequence of procedures was then analyzed by conventional and real-time IS900-based PCR in order to detect M. avium subsp. paratuberculosis ...
  48. [48]
    Application of IS900 PCR for Detection of Mycobacterium avium ...
    A polymerase chain reaction (PCR)-based assay was developed for detection of insertion sequence 900 (IS900) of Mycobacterium avium subsp. paratuberculosis ...
  49. [49]
    Evaluation of IS900-PCR assay for detection of Mycobacterium ...
    Results from our study suggest that IS900 PCR assay using bulk tank milk may not be useful for screening herds with M. avium subsp. paratuberculosis infected ...
  50. [50]
    Johne's Disease in Domesticated and Wild Animals - NCBI - NIH
    The incubation period for JD also is variable but often protracted, ranging from 4 months to 15 years (Macindoe, 1950; Smyth and Christie, 1950). In oral ...
  51. [51]
    Comparison of Bacterial Culture, Histopathology, and ...
    The aim of this study was to evaluate and compare histopathology in conjunction with acid-fast staining and IHC in the diagnosis of Johne's disease in tissues ...
  52. [52]
    Histo- (microscopic) pathology - Johne's Information Center
    H&E stained section of bovine intestine showing the granulomatous inflammation characteristic of Johne's disease. Multi-nucleated giant cell commonly found ...
  53. [53]
    Use of Loop-Mediated Isothermal Amplification of the IS900 ...
    These results indicate that LAMP can provide a rapid yet simple test for the detection of MAP. Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne's ...
  54. [54]
    Use of loop-mediated isothermal amplification of the IS900 ...
    We evaluated the usefulness of loop-mediated isothermal amplification (LAMP) in detecting specific gene sequences of Mycobacterium avium subsp.
  55. [55]
    Development and validation of a loop‐mediated isothermal ...
    Apr 19, 2019 · The aim of this study was to design an assay for the identification of Mycobacterium avium subsp. paratuberculosis (MAP) to be used in ...
  56. [56]
    MAP, Johne's disease and the microbiome; current knowledge ... - NIH
    May 7, 2021 · Strains of MAP are notoriously difficult to isolate, often taking months to grow in pure culture, thereby making the detection and diagnosis of ...
  57. [57]
    Johne's disease | Veterinary Medicine Extension | Washington State ...
    Dec 14, 2023 · It is worth noting that unfortunately fecal PCR has limitations as well. Infected animals that are shedding MAP do not necessarily shed ...
  58. [58]
    Diagnostics - Diagnosis and Control of Johne's Disease - NCBI
    At the herd level, tests will tend to perform better as the proportion of individuals in more advanced stages of disease increases.
  59. [59]
    Characteristics (sensitivity and specificity) of herd-level diagnostic ...
    In that review, ELISA tests were reported to have a sensitivity (Se) and specificity (Sp) of 7–22% and 85–100% respectively, while faecal culture was reported ...Results · Serology-Based Test Methods · Organism Detection Test...
  60. [60]
    Evaluation of Environmental Sampling for Detection of ... - PMC
    The objective of this study was to evaluate a novel environmental sampling protocol for measurement of MAP contamination of the calf environment on infected ...Missing: wildlife lack
  61. [61]
    Diagnosis of tuberculosis in wildlife: a systematic review
    Feb 24, 2021 · However, diagnosis in wildlife is challenging due to the wide taxonomic diversity, the capture and restraint difficulties inherent to wildlife ...
  62. [62]
    Seroprevalence of Mycobacterium avium subsp. paratuberculosis in ...
    Prevalence estimates have generally been higher for dairy cattle than for beef cattle (7). In North America, a study conducted in the 17 main dairy U.S. states ...
  63. [63]
    Paratuberculosis: A Potential Zoonosis and a Neglected Disease in ...
    Jul 5, 2020 · Due to the limited research on paratuberculosis in Africa, in spite of growing global concerns, it may rightfully be considered a neglected ...Missing: intensification | Show results with:intensification
  64. [64]
    Genotyping methods and molecular epidemiology of Mycobacterium ...
    Based on the host from which MAP strains were first isolated, researchers proposed cattle (C) and sheep (S) type strains as the two main MAP types infecting ...
  65. [65]
    [PDF] chapter 3.1.16. - paratuberculosis (johne's disease) - WOAH
    Paratuberculosis is found most often among domestic ruminants (cattle, sheep, goats, camelids and buffaloes) as well as wild ruminants (cervids) and has a ...
  66. [66]
    Changes in the Johne's disease situation in GB dairy herds over 10 ...
    Other European countries have estimated lower herd prevalences of JD. The Lombardy region of Italy found a herd prevalence of 52.4 %, based on serum ELISA data ...3. Results · 4. Discussion · 4.1. Jd Prevalence And...Missing: worldwide | Show results with:worldwide
  67. [67]
    Paratuberculosis - WOAH - World Organisation for Animal Health
    Paratuberculosis, also known as Johne's disease, is a chronic, contagious bacterial disease of the intestinal tract that primarily affects sheep and cattle.Missing: prevalence | Show results with:prevalence
  68. [68]
    Johne's (Paratuberculosis) - NADIS
    Vaccinated herds/flocks have much reduced clinical cases and losses but Johne's disease will not be eradicated. Vaccination may be the most cost-effective ...Missing: percentage | Show results with:percentage
  69. [69]
    Paratuberculosis: The Hidden Killer of Small Ruminants - MDPI
    In Australia, the average annual mortality rate due to PTB in 12 sheep flocks was reported to vary between 6.2 and 7.8%, resulting in a 6.4 and 8.5% decrease of ...
  70. [70]
    [PDF] An outbreak of Johne's disease in a newly established commercial ...
    Fifty goats (40 young and 10 adult) died in 1 month (Jan. to. Feb., 2006) from clinical JD, due to weakness, diarrhoea and tympanitis. Morbidity was. 100% and ...
  71. [71]
    Control Principles and Programs - Diagnosis and Control of Johne's ...
    Important practices that must be adopted before entry into the program are the prevention of commingling, the prevention of exposure to the manure or raw milk ...
  72. [72]
    [PDF] Uniform Program Standards for the Voluntary Bovine Johne's ...
    Sep 1, 2010 · The program consists of three basic elements: 1) education to inform producers about the cost of JD and to provide information about management.
  73. [73]
    Johne's Disease | USU
    This is a hardy organism which survives long term in the environment and has a very long incubation period in the animal before producing clinical disease (2-4 ...
  74. [74]
    [PDF] How to Do Risk Assessments and Management Plans for Johne's ...
    Before developing a herd management plan, a risk assessment must be conducted to identify of management practices that allow M. paratuberculosis to spread ...
  75. [75]
    Johne's Disease Research Reveals Promise - Tellus
    Another, potentially simpler, therapeutic treatment is a nutritional supplement: vitamin D . “One thing we noted early on is that vitamin D is lacking in cows ...
  76. [76]
    [PDF] Therapy for Johne's Disease - The Bovine Practitioner
    Finally, animals with clinical Johne's Disease are known to excrete large ... Supportive treatment with fluids and antibiotics was given during these episodes.Missing: care nutritional supplements
  77. [77]
    [PDF] Paratuberculosis Vaccination
    EFFICACY OF JOHNE'S DISEASE VACCINATION. JD vaccine does not prevent all new infections; efficacy may depend on age of exposure versus age of vaccination ...
  78. [78]
    Significant reduction in bacterial shedding and improvement in milk ...
    Nov 22, 2009 · This trial was implemented as a field assay to test the efficacy of a new paratuberculosis vaccine specifically designed for use in cattle and ...<|control11|><|separator|>
  79. [79]
    Effectiveness of Gudair™ vaccine for the control of ovine Johne's ...
    Effectiveness of Gudair™ vaccine for the control of ovine Johne's disease in flocks vaccinating for at least 5 years · Abstract · Publication types · MeSH terms.Missing: Johnevac | Show results with:Johnevac
  80. [80]
    Immunization With a DNA Vaccine Cocktail Induces a Th1 ... - PubMed
    Aug 12, 2008 · Immunization With a DNA Vaccine Cocktail Induces a Th1 Response and Protects Mice Against Mycobacterium Avium Subsp. Paratuberculosis Challenge.
  81. [81]
    Mycobacterium paratuberculosis zoonosis is a One Health emergency
    Jun 2, 2022 · Mycobacterium avium subspecies paratuberculosis—MAP—is the cause of Johne's disease of ruminant animals. MAP contaminates food, the environment ...
  82. [82]
    Mycobacterium avium subspecies paratuberculosis - PubMed Central
    May 19, 2018 · Infection with this microorganism results in substantial farming economic losses and animal morbidity.Missing: mortality | Show results with:mortality
  83. [83]
    The evidence for Mycobacterium avium subspecies ...
    This microbe is transmitted to humans through various means, including contact with animal faeces, contaminated dust and soil, organic fertilizers, and as ...<|control11|><|separator|>
  84. [84]
  85. [85]
  86. [86]
    Current status of Mycobacterium avium subspecies paratuberculosis ...
    Prevalence of MAP was higher in large ruminants (24.1% in cattle and buffaloes) as compared to small ruminants (22.5% in sheep and goat). Seropositivity was ...
  87. [87]
    Mycobacterium avium ss. paratuberculosis Zoonosis – The Hundred ...
    The factitive role of Mycobacterium avium ss. paratuberculosis (MAP) in Crohn's disease has been debated for more than a century.
  88. [88]
    Mycobacterium avium subspecies paratuberculosis (MAP) infection ...
    Oct 14, 2024 · With preponderance of evidence, our findings confirm the role of MAP infection in gut microbiota of patients with multiple sclerosis.
  89. [89]
    Mycobacterium avium ss. paratuberculosis Zoonosis - PubMed Central
    Mar 4, 2015 · The factitive role of Mycobacterium avium ss. paratuberculosis (MAP) in Crohn's disease has been debated for more than a century.
  90. [90]
    Culture of Mycobacterium avium subspecies paratuberculosis from ...
    Sep 24, 2004 · MAP DNA in uncultured buffy coats was identified by PCR in 13 (46%) individuals with Crohn's disease, four (45%) with ulcerative colitis, ...
  91. [91]
    Mycobacterium avium subspecies paratuberculosis (MAP) and ...
    This question has been debated over the past century, with conflicting data suggesting MAP may play a causal role or rather may be a bystander or possibly play ...
  92. [92]
    Mycobacterium avium subspecies paratuberculosis and Crohn's ...
    This systematic review assesses the evidence for an association between Mycobacterium avium subspecies paratuberculosis (MAP) and Crohn's disease.
  93. [93]
    Profound remission in Crohn's disease requiring no further treatment ...
    Apr 9, 2020 · Ten patients were identified to have achieved prolonged remission for 3–23 years (median 8.5 years). Of these, 7/10 took targeted Anti-MAP ...
  94. [94]
    Targeted Combination Antibiotic Therapy Induces Remission ... - MDPI
    Mar 6, 2020 · AMAT treatment consisted of rifabutin, clofazimine and clarithromycin, plus either ciprofloxacin, metronidazole or ethambutol. Symptoms, ...1. Introduction · 3. Results · 4. Discussion
  95. [95]
    Putting Crohn's on the MAP: Five Common Questions on the ... - NIH
    Oct 22, 2020 · Recent discoveries continue to implicate MAP as the initial promoter of Crohn's disease through direct and indirect effects of inflammation.
  96. [96]
    NOD2 in Crohn's Disease—Unfinished Business - PMC - NIH
    NOD2 is the most widely implicated gene in the aetiology of Crohn's disease [CD]. The role of NOD2 in the development of CD has been acknowledged for over 20 ...
  97. [97]
    NOD2 and Crohn's Disease Clinical Practice: From Epidemiology to ...
    Apr 6, 2024 · NOD2 mutations are present in up to 10%-27% of patients with CD. The risk of developing CD is 3-fold higher in heterozygotes and 20-40 times ...Abstract · Introduction · NOD2 Variants Epidemiology · NOD2 and Diagnosis
  98. [98]
    [PDF] Crohn's Disease and Mycobacterium avium paratuberculosis (MAP)
    A particular bacteria, Mycobacterium avium paratuberculosis (MAP), has generated interest as a potential trigger for Crohn's disease because it causes an ...
  99. [99]
    Assessment of listing and categorisation of animal diseases within ...
    Jul 28, 2017 · Serological surveillance for paratuberculosis on 627 of New Zealand's deer farms has been carried out since 2000, using blood samples submitted ...
  100. [100]
    Reportable Diseases - Illinois Department of Agriculture
    *Diseases in bold with an asterisk are considered foreign animal diseases and should be IMMEDIATELY reported to the State Veterinarian's office at 217-782-4944 ...Missing: EU | Show results with:EU
  101. [101]
    Johne's Disease Program Sampling and Testing Guidance
    Our recommended test for screening for MAP infection in clinical or non-clinical goats is the Johne's fecal PCR test.